Time-Series Modeling of Multiple Sclerosis Disease Activity: A Promising Window on Disease Progression and Repair Potential?

Neurotherapeutics

Volumn 4, Issue 3, 2007, Pages 485-498

  Meier, Dominik S ^a   Weiner, Howard L ^b   Guttmann, Charles R G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

disease modeling; lesion evolution; morphometry; Multiple sclerosis; repair; serial MRI

Indexed keywords

ANISOTROPY; ARTICLE; DEMYELINATION; DIFFUSION TENSOR IMAGING; DISEASE ACTIVITY; DISEASE COURSE; HISTOLOGY; HUMAN; IN VIVO STUDY; LEUKODYSTROPHY; MULTIPLE SCLEROSIS; MYELIN DEFICIENCY; MYELINATION; NERVE DEGENERATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERIPHERAL NERVE; PHENYLKETONURIA; PRIORITY JOURNAL; REMYELINIZATION; SCHIZOPHRENIA;

ANIMALS; BRAIN; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MODELS, NEUROLOGICAL; MULTIPLE SCLEROSIS; NERVE REGENERATION; TIME;

EID: 34250761334     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2007.05.008     Document Type: Article

References (51)

1. Weinshenker B.G., Bass B., Rice G.P., et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112 (1989) 133-146
2. Runmarker B., and Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 116 (1993) 117-134
3. Kutzelnigg A., Lucchinetti C.F., Stadelmann C., et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128 (2005) 2705-2712
4. Prineas J.W., Kwon E.E., Cho E.S., et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 50 (2001) 646-657
5. Filippi M., Rovaris M., Iannucci G., et al. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 55 (2000) 1714-1718
6. Molyneux P.D., Kappos L., Polman C., et al. European Study Group on Interferon β-1b in Secondary Progressive Multiple Sclerosis. The effect of interferon β-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain 123 (2000) 2256-2263
7. Paolillo A., Coles A.J., Molyneux P.D., et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53 (1999) 751-757
8. Tremlett H., and Devonshire V. Is late-onset multiple sclerosis associated with a worse outcome?. Neurology 67 (2006) 954-959
9. Tintore M., Rovira A., Rio J., et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 67 (2006) 968-972
10. Chard D.T., Brex P.A., Ciccarelli O., et al. The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study. J Neurol Neurosurg Psychiatry 74 (2003) 1551-1554
11. Confavreux C., Vukusic S., and Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126 (2003) 770-782
12. Weinshenker B.G., Bass B., Rice G.P., et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112 (1989) 1419-1428
13. Kappos L., Traboulsee A., Constantinescu C., et al. Long-term subcutaneous interferon β-1a therapy in patients with relapsing-remitting MS. Neurology 67 (2006) 944-953
14. Minneboo A., Uitdehaag B.M., Adèr H.J., et al. Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients. Neurology 65 (2005) 56-61
15. Truyen L., van Waesberghe J.H., van Walderveen M.A., et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 47 (1996) 1469-1476
16. van Waesberghe J.H., van Walderveen M.A., Castelijns J.A., et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 19 (1998) 675-683
17. Rudick R.A., Lee J.C., Simon J., and Fisher E. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol 60 (2006) 236-242
18. Cotton F., Weiner H.L., Jolesz F.A., and Guttmann C.R. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 60 (2003) 640-646
19. Kalkers N.F., Ameziane N., Bot J.C., et al. Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol 59 (2002) 1572-1576
20. Kappos L., Moeri D., Radue E.W., et al. Gadolinium MRI Meta-analysis Group. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet 353 (1999) 964-969
21. Agosta F., Rovaris M., Pagani E., et al. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain 129 (2006) 2620-2627
22. Schmierer K., Scaravilli F., Altmann D.R., et al. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 56 (2004) 407-415
23. van Waesberghe J.H., Kamphorst W., De Groot C.J., et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 46 (1999) 747-754
24. Miller D.H., Albert P.S., Barkhof F., et al. US National MS Society Task Force. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 39 (1996) 6-16
25. Filippi M., Horsfield M.A., Adèr H.J., et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 43 (1998) 499-506
26. Erskine M.K., Cook L.L., Riddle K.E., et al. Resolution-dependent estimates of multiple sclerosis lesion loads. Can J Neurol Sci 32 (2005) 205-212
27. Filippi M., Rovaris M., Capra R., et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis: implications for phase II clinical trials. Brain 121 (1998) 2011-2020
28. Ingle G.T., Sastre-Garriga J., Miller D.H., and Thompson A.J. Is inflammation important in early PPMS?. a longitudinal MRI study. J Neurol Neurosurg Psychiatry 76 (2005) 1255-1258
29. Molyneux P.D., Filippi M., Barkhof F., et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 43 (1998) 332-339
30. Miller D.H., Molyneux P.D., Barker G.J., et al. European Study Group on Interferon-β1b in Secondary Progressive Multiple Sclerosis. Effect of interferon-β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. Ann Neurol 46 (1999) 850-859
31. Jacobs L.D., Cookfair D.L., Rudick R.A., et al. Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39 (1996) 285-294
32. IFNB Multiple Sclerosis Study Group, and University of British Columbia MS/MRI Analysis Group. Interferon β-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45 (1995) 1277-1285
33. Li D.K., and Paty D.W. Prevention of Relapses and Disability by Interferon-β1a Subcutaneously in Multiple Sclerosis. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Ann Neurol 46 (1999) 197-206
34. Filippi M., Horsfield M.A., Tofts P.S., et al. Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain 118 (1995) 1601-1612
35. Isaac C., Li D.K., Genton M., et al. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology 38 (1988) 1511-1515
36. Willoughby E.W., Grochowski E., Li D.K., et al. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 25 (1989) 43-49
37. Lee M.A., Smith S., Palace J., and Matthews P.M. Defining multiple sclerosis disease activity using MRI T2-weighted difference imaging. Brain 121 (1998) 2095-2102
38. Brex P.A., Ciccarelli O., O'Riordan J.I., et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346 (2002) 158-164
39. Weiner H.L., Guttmann C.R., Khoury S.J., et al. Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage. J Neuroimmunol 104 (2000) 164-173
40. Khoury S.J., Guttmann C.R., Orav E.J., et al. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch Neurol 57 (2000) 1183-1189
41. Bitsch A., Kuhlmann T., Stadelmann C., et al. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann Neurol 49 (2001) 793-796
42. Bagnato F., Jeffries N., Richert N.D., et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 126 (2003) 1782-1789
43. Meier D.S., and Guttmann C.R. Time-series analysis of MRI intensity patterns in multiple sclerosis. Neuroimage 20 (2003) 1193-1209
44. Meier D.S., and Guttmann C.R. Time-series modeling of MS lesion development. Neuroimage 32 (2006) 531-537
45. Lucchinetti C., Bruck W., Parisi J., et al. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: a study of 113 cases. Brain 122 (1999) 2279-2295
46. Lucchinetti C., Bruck W., Parisi J., et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47 (2000) 707-717
47. Patrikios P., Stadelmann C., Kutzelnigg A., et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129 (2006) 3165-3172
48. Lassmann H. Recent neuropathological findings in MS-implications for diagnosis and therapy. JNeurol 251 Suppl 4 (2004) IV2-IV5
49. Schwartz M., and Kipnis J. Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases. J Neurol Sci 233 (2005) 163-166
50. van Waesberghe J.H., van Walderveen M.A., Castelijns J.A., et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 19 (1998) 675-683
51. Filippi M., Rovaris M., Rocca M.A., et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes.". Neurology 57 (2001) 731-733